Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of antifibrotic therapy on regression of myocardial fibrosis after TAVI
DRKS00019893Phase 2Not yet recruiting
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of spironolactone and dihydralazine in aortic stenosis (AS), heart failure (HF) and cardiac fibrosis (3 arms), sponsored by Universitätsmedizin Göttingen. Primary endpoint: Regression of myocardial fibrosis after TAVI. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
spironolactonedihydralazine
03
Conditions
aortic stenosis (AS)heart failure (HF)cardiac fibrosis
Beyond the preview
Go deeper on DRKS00019893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00019893.